Kornimate/medical-research-clean huggingface dataset:
efficacy of nebulized pulmicort respules in primary lung cancer patients with copd

Conditions: Post Operative Complication, Pulmonary; Lung Cancer; COPD

Summary: to test the hypothesis that nebulized pulmicort respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with copd. compare post-operation pulmonary complication incidence in two treatment arms among primary lung cancer patients with copd required single lobectomy from 3days before operation to 7 days after operation.


Eligibility criteria:
inclusion criteria: 1. newly diagnosed or existing copd defined by gold, and fev1 of\<80% predicted and fev1/fvc\<70% 2. diagnosed as primary lung cancer by china guidelines on diagnosis and treatment of primary lung cancer 3. .consistent with indication of operation of pulmonary single lobectomy surgery by china guidelines on diagnosis and treatment of primary lung cancer 4. general anesthesia and double cavity intubation was used during operation 5. asa classification of anesthesia risk is in category 1-3 both in baseline 6. age from 40-80 years old 7. smoking cessation more than two weeks before operation 8. sp o2\>90% before surgery 9. hemoglobin \> 10g/dl 10. estimated duration of surgery \< 4 hours 11. 18.5\<bmi \< 28 exclusion criteria: 1. patients who had taken systemic corticosteroids in the preceding 1month before baseline 2. patients who had pneumonia in the preceding 1month before baseline 3. patients with a history of recent myocardial infarction, heart failure, tuberculosis 4. subject with known or suspected human immunodeficiency virus infection

Keywords: primary lung cancer patients
transluminal or percutaneous endoscopic drainage and debridement of abcesses after bariatric surgery

Conditions: Obesity; Sepsis

Summary: patients presenting intra-abdominal abcesses following bariatric surgery complicated by fistulae are classically treated by external drainage and endoprosthesis or surgical redo. morbidity and mortality being increased in case of necrotic collections, an endoscopic debridement treatment might be proposed in certain cases. this present study aim to review the evolution of the patients treated by this method from 2007 to 2011 in the investigators institution.

this retrospective study in an academic tertiary center will review the files of patients who underwent endoscopic drainage and debridement of abdominal abscesses secondary to bariatric surgery leaks . the decision for endoscopic treatment was made by the medico-surgical team in charge of this type of surgery, who had to weigh the high risk of mortality in case of re-intervention, along with endoscopic access to abscesses via the transluminal or percutaneous route based on abdominal imaging. data collection will lead to the evaluation of the technical success rate, the clinical success and potential complications.

Eligibility criteria:
inclusion criteria: * all the patient treated in an academic tertiary center who underwent endoscopic drainage and debridement of abdominal abscesses secondary to bariatric surgery leaks from october 2007 to april 2011 * septic state exclusion criteria: * all other necrosectomies performed for pancreatic disorders were excluded from the study

Keywords: leaks after bariatric surgery fistulae after bariatric surgery abdominal abcesses and bariatric surgery endoscopic drainage of abcesses percutaneous drainage of abcesses gastric bypass sleeve gastrectomy necrotic collection and bariatric surgery
a study of delavirdine used together with other anti-hiv drugs in hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give delavirdine (dlv) in combination with two or three other drugs to hiv-infected patients. the drugs to be used in combination with dlv are zidovudine (zdv), indinavir (idv), and lamivudine (3tc).

in this open-label pilot study, patients are randomized to 1of the following 4 arms for 24 weeks: arm 1 (40 patients): dlv plus zdv plus idv. arm 2 (40 patients): dlv plus idv plus 3tc\*. arm 3 (40 patients): dlv plus zdv plus idv plus 3tc. arm 4 (40 patients): zdv plus idv plus 3tc. * dose determined by body weight. patients may opt to continue on study for 24 additional weeks at the discretion of the investigator.

Eligibility criteria:
inclusion criteria prior medication: allowed: less than 1 month prior treatment with zidovudine. exclusion criteria prior medication: excluded: * prior indinavir. * prior lamivudine. * prior protease inhibitors. * prior non-nucleoside reverse transcriptase inhibitors. * 1 month or more prior zidovudine. 1. hiv-1 positive. * cd4 coun tis above 50. * hiv-1 rna levels greater than 20,000.

Keywords: hiv-1 zidovudine hiv protease inhibitors lamivudine indinavir rna, viral delavirdine reverse transcriptase inhibitors viral load
development of a lifestyle physical activity intervention to reduce risk for perinatal cannabis use - rct

Conditions: Pregnancy

Summary: the overall goal of this pilot study is to develop and preliminarily evaluate an lpa intervention designed to reduce cannabis use during pregnancy.

in the pilot rct, we will recruit 50 women between 12-22 weeks gestation from an established network of prenatal clinics, and randomly assign eligible women to either a: 1) lpa+fitbit intervention or 2) fitbit only control condition. similar to our prior trials with pregnant women, the intervention period will be 12 weeks in duration during pregnancy, with follow-ups extending to the end of pregnancy and into the postpartum period. major assessments will occur at baseline, end of treatment (eot), and 4 weeks postpartum; we will also conduct brief phone surveys at three points in between the larger assessments. participants will complete a 7-day period of accelerometry and urine toxicology screens following each major assessments. birth record abstractions to collect information about specific outcomes (pre-term delivery, low birth weight) will be conducted by trained staff at one month post-birth.

Eligibility criteria:
inclusion criteria: 1. women 18+ years of age 2. 12-25 weeks gestation with a healthy singleton pregnancy 3. medically-cleared by their prenatal provider for moderate intensity physical activity 4. self-report of cannabis use at least once/week in the 3 months prior to the current pregnancy and desire to not engage in prenatal cu 5. current psychological distress as defined by edinburgh postnatal depression scale score \>7 and/or generalized anxiety disorder 7 score \>5) 6. english-speaking 7. owns a smartphone to enable use of the fitbit app 8. current physical activity level does not meet public health recommendations (less than 150 minutes/week moderate intensity physical activity for the past 3 months) 9. expresses interest in reducing or discontinuing cu exclusion criteria: 1. current dsm-5 diagnosis of moderate/severe substance use disorder other than cannabis use disorder or nicotine use disorder 2. use of illicit substances in the last 3 months (other than cannabis) 3. acute psychotic symptoms 4. current or recent suicidality or homicidality 5. current anorexia or bulimia 6. current cognitive impairment 7. physical or medical problems that would not allow safe participation in moderate intensity physical activity 8. has plan to relocate away from the geographic area during the study intervention or assessment period 9. recently started a new form of mental health or substance use treatment within the past 4 weeks
an investigation to evaluate a new donor site dressing in surgical burn patients

Conditions: Donor Site Complication

Summary: the investigator will identify the test donor site and test location will be considered on the upper anterior thighs as being the most suitable if available. circumferential donors will be considered acceptable as well. treatment will be initiated in the operation room following debridement and split thickness grafting of wounds. donors will be harvested at 0.010 - 0.012 in. thickness. treatment and dressing of test donor site will include hemostasis post harvesting with epinephrine-soaked lap sponges. once adequate hemostasis is achieved, a mepilex transfer ag dressing will be applied directly to study site. secondary dressing will include covering with ace wrap. healing should be asses after 10-14 days.

a prospective, open, non-controlled clinical investigation to evaluate the adequacy of donor site healing when using a new donor site dressing, mepilex transfer ag approximately 20 subjects from 2 centres in the us, presenting with the need for surgical intervention and grafting for burn injury will be enrolled. eligible subjects will have a selected donor site designated as a "study site".

Eligibility criteria:
inclusion criteria: 1. surgical donor sites for deep partial-thickness or full-thickness burns 2. burn of thermal origin 3. both genders with an age ≥ 7 years at enrolment 4. signed informed consent 5. subjects who are younger than the legal consenting age must in addition to their own assent form have a signature from a legally authorized representative. exclusion criteria: 1. any known or suspected systemic infection 2. any known sensitivity to silver or other components/products used in this study. 3. any active, uncontrolled, progressive or untreated malignancy. a subject who has had a malignant disease in the past, was treated with the expectation of a cure and is currently disease-free, may be considered for study entry. 4. use of penicillamine, corticosteroid or immunosuppressive medication within 2 months prior to enrollment, or current use of nonsteroidal anti- inflammatory agents which cannot be discontinued, or who is likely to be prescribed these medications or any other medications known to adversely affect wound healing during study participation. 5. major uncontrolled systemic disorders such as hepatic, renal, neurologic, or endocrinologic disorders. 6. requires immersion hydrotherapy at any time during study participation (note, showering hydrotherapy is allowed). 7. subject unwilling to comply with 28 day follow-up. 8. participation in another investigational study while participating in this study. 9. bleeding disorders
machine learning-based classification of symptom clusters and online cbt

Conditions: Depression and Anxiety Symptom

Summary: to breakthrough the bottleneck identified, we will conduct a cross-sectional study to develop a symptom clustering model for depression and anxiety. a wide range of statistical methods as well as machine learning approaches were explored, and a cohesive hierarchical clustering algorithm will be used. after developing the model, a symptom-matched intervention program based on problem solving therapy will be formulated. we are supposed to examine whether its use for personalizing symptom-matched psychological treatment can lead to improved patient outcomes, compared with usual care. this project is expected to provide a new and precise method for the emotion management, which will provide a standardized intervention pathway combining screening with treatment for the management of depression symptom and anxiety symptom. a preciser intervention matched to individual symptoms may provide important insight in improving patient outcome as well as a standardized mood management pathway targeting to the early detection and intervention for community residents.


Eligibility criteria:
inclusion criteria: * meets the criteria of phq-9 and or gad-7 ≥5 at baseline measurements exclusion criteria: * patients who report the presence of suicidal thoughts in entry 9 of the phq-9 on any psychometric measurements, referred to the wuhan psychological hotline platform; and * those who are currently suffering from mental illness or are being treated with antipsychotic drugs; * women during pregnancy or within 3 months after delivery.

Keywords: machine learning approach cbt
assessment of the effect of a novel surface roughness treatment on dental implants on integration success

Conditions: Partial Edentulism; Tooth Disease

Summary: a study where dental implants with different roughened surfaces will be evaluated for the ability to resist countertorque forces.

this study on dental implants with different roughened surfaces will assess its ability to resist countertorque testing at various study time points and demonstrate high success

Eligibility criteria:
inclusion criteria: * patients of either sex and older than 18 years of age * patients needing at least one dental implant to treat partial edentulism * patients physically able to tolerate surgical and restorative dental procedures * patients agreeing to all protocol visits exclusion criteria: * patients with infection or severe inflammation at the intended treatment sites * patients smoking greater than 10 cigarettes per day * patients with uncontrolled diabetes mellitus * patients with uncontrolled metabolic diseases * patients who received radiation treatment to the head in the past 12 months * patients needing bone grafting at the intended treatment sites * patients known to be pregnant at screening visit * patients with para-functional habits like bruxing and clenching

Keywords: edentulism dental implants clinical study randomized osseotite certain tapered crestal bone level
forearm immobilization, metabolic health, and nutrition

Conditions: Healthy

Summary: the present study will investigate the impact of dietary branched chain amino acid restriction on muscle atrophy, insulin sensitivity and muscle protein synthesis following short-term forearm immobilization

twenty-four healthy young volunteers will undergo 2 days of forearm immobilization in combination with either a branched chain amino acid restricted diet or a control diet. before and after immobilization, they will receive a stable isotope tracer infusion (5.5 h) combined with repeated blood and muscle sampling under insulin clamp conditions, in order to measure insulin sensitivity and muscle protein synthesis in the fasted and fed state.

Eligibility criteria:
inclusion criteria: * males and females 18-40 years of age * body mass index between 18.5 and 30 kg/m2 exclusion criteria: * smoking * any diagnosed metabolic impairment (e.g. type 1 or 2 diabetes) * any diagnosed cardiovascular disease * hypertension (≥140 mmhg systolic and/or ≥90 mmhg diastolic) * chronic use of any prescribed or over the counter pharmaceuticals (excluding oral contraceptives and contraceptive devices) * regular use of nutritional supplements * currently involved in a structured progressive resistance training programme (\>3 times per week) * a personal or family history of thrombosis, epilepsy, seizures or schizophrenia * any previous motor disorders or disorders in muscle and/or lipid metabolism * known hypokalaemia * presence of an ulcer in the stomach or gut and/or strong history of indigestion * known severe kidney problems * pregnant or breastfeeding * unable to give consent
xamiol®gel in body psoriasis: a one-year non-interventional study

Conditions: Psoriasis Vulgaris

Summary: this study aims to describe the patient population treated and the real-life patients' experiences with xamiol®gel in the long term, up to 52 weeks management of body psoriasis vulgaris in russia. the result will increase the knowledge on xamiol®gel enabling dermatologists and patients to optimize its use in the long term management of psoriasis.


Eligibility criteria:
inclusion criteria: * psoriasis vulgaris on body * patients planned to receive topical treatment on the body with calcipotriol/betamethasone gel * written informed consent exclusion criteria: * no or very mild symptoms of psoriasis vulgaris on the body at study start * any on-going treatments at study start with topical steroids, salicylic acid or its combination * other topical treatment for body psoriasis * pregnancy or planned pregnancy within treatment period * contraindications according to prescribing information.
injection of ranibizumab versus combination of ranibizumab and triamcinolone acetate for (crvo)

Conditions: Ophthalmopathy

Summary: to compare the clinical effectiveness of ranibizumab and combination of ranibizumab and triamcinolone for the treatment of macular oedema secondary to crvo


Eligibility criteria:
inclusion criteria: * patients 18 years of age or older with visual impairment resulting from macular edema secondary to crvo. * a bcva approximate snellen equivalents, 20/40. exclusion criteria: * use of intra-vitreal anti-vegf injections 3 months or less before baseline. * pan-retinal laser photocoagulation 3 months or less before baseline, * topical ocular or systemic corticosteroids administered for 30 consecutive days. * intraocular or periocular corticosteroid use 3 months or less before screening (study eye), * use of intraocular corticosteroid implants, * uncontrolled glaucoma (intraocular pressure \[iop\] 30 mmhg with medication) at the time of screening or baseline, * iris neovascularization or neo-vascular glaucoma.
exome sequencing in autistic spectrum disorder

Conditions: Autism Spectrum Disorder; Autism; Autistic Disorder

Summary: background: * research into the genetic causes of autism spectrum disorder (asd) involves studies of the dna of children with autism. new dna sequencing technology allows researchers to study specific genes in search of genetic changes that may cause or contribute to asd. individuals who donated dna to the autism genetic resource exchange may benefit from further study of their dna samples with more advanced dna sequencing technology. * the role of cholesterol in individuals with asd is currently under investigation. research has suggested that abnormal cholesterol levels in children with autism may be related to genetic mutations or changes in how cholesterol is regulated in the body. objectives: - to study existing blood samples of children with autism spectrum disorders to evaluate the relationship between genetic traits and cholesterol function. eligibility: - children with asd who donated blood samples to the autism genetic resource exchange. design: * parents/guardians of minor children with asd will provide consent for further research to be performed on existing dna samples in the autism genetic research exchange databank. information from this research may be provided to the consenting parents/guardians on a case by case basis, as directed by the researchers.

autism spectrum disorder (asd) is a neurodevelopmental disorder characterized by functional deficits in three domains: social interaction, communication, and stereotypic behavior. prevalence has been estimated to be approximately 1/166 children and the public health impact is significant. asd clearly has a genetic component; however, identification of specific etiologies has been complicated by the heterogeneous nature of asd. one approach to minimize this problem is to define endophenotypes that can subcategorize asd patients. based on our work with smith-lemli-opitz syndrome, we have investigated whether alterations in cholesterol homeostasis may contribute to asd. we found in 200 asd subjects that 23% of subjects had serum cholesterol levels less than or equal to 2.28th centile and 9% had levels greater than or equal to 97.72nd centile. analysis of the sterol profile suggested that the hypocholesterolemia was due to a synthetic defect rather than decreased oral intake. thus we hypothesize that asd patients with abnormal cholesterol levels will have polymorphisms or mutations of either genes involved in cholesterol homeostasis or genes encoding proteins whose function is altered by changes in cholesterol levels. to test this hypothesis we propose to 1) use serum cholesterol levels to define asd endophenotypes and 2) to perform genomic resequencing of all known exons in hypo- and normocholesterolemic asd patients.

Eligibility criteria:
* inclusion criteria: 1. prior participation in autism genetic research exchange 2. multiple affected children with asd 3. willingness to contact the nih and reconsent

Keywords: autism spectrum disorder cholesterol exome sequencing autistic spectrum disorder asd
new biological tests in patients with antiphospholipid antibodies

Conditions: Antiphospholipid Syndrome

Summary: antiphospholipid syndrome (aps) is an autoimmune disease characterized by thromboembolic events or pregnancy complications associated with circulating antiphospholipid antibodies (apl-abs). aps diagnosis needs the presence of both clinical and serological criteria (saporro criteria, updated with sydney criteria in 2006). however, no correlation between laboratory assays and the clinical thrombosis risk in patients with apl-abs was observed as only few patients with apl-abs developed clinical manifestations. thrombin generation assays (tga) is a global coagulation test that may represent a certain interest to evaluate thrombosis risk as a high thrombin generation capacity seems to be an independent risk factor for recurrent thromboembolic events. another point of interest to assess the thrombotic risk is the detection of autoantibodies recognizing domain 1 of β2gp1 (aβ2gp1-dm1). these autoantibodies are strongly related correlated with thrombotic and pregnancy manifestations. recently, a commercial chemiluminescence immunoassay (clia) for detection of aβ2gp1-dm1 became available on acustar® analyzer (hemosil acustar®, instrument laboratory, bedford, usa) to facilitate aβ2gp1-dm1 research. the aim of this study is to evaluate two additional laboratory assays to improve the correlation between laboratory assays and the clinical thrombosis risk in patients with antiphospholipid (apl): thrombin generation assay and aβ2gp1-dm1. each biological result (antibodies to domain 1 (dm1) of β2-glycoprotein 1 (aβ2gp1-dm1) and thrombin generation test (tgt) parameters: endogen thrombin potential (etp), lag time and time to peak) will be compared to the history of clinical thrombosis (venous or arterial thrombosis and/or obstetrical complications such as defined by the saporro criteria updated with sydney criteria in 2006) for each patient.


Eligibility criteria:
inclusion criteria: * adult patients with confirmed apl-abs (at least two positive determinations at least 12 week apart) * subject non opposition exclusion criteria: * age \< 18 years * patient under the protection of justice, under guardianship or under curatorship * patient with anticoagulant treatment, except heparin * clinically symptomatic liver disease, supported by e.g. diagnosis of cirrhosis, portal hypertension, ascites, pt superior or egal to 5 seconds above upper normal limit * platelet count \< 100 g/l (giga/liter) * poor venous access * non confirmed suspicion of aps